| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | steroid hydroxylase activity | 1.11e-03 | 34 | 29 | 2 | GO:0008395 | |
| GeneOntologyMolecularFunction | aromatase activity | 1.18e-03 | 35 | 29 | 2 | GO:0070330 | |
| GeneOntologyMolecularFunction | oxygen binding | 1.31e-03 | 37 | 29 | 2 | GO:0019825 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 2.30e-03 | 49 | 29 | 2 | GO:0016712 | |
| Domain | Cyt_P450_E_grp-I | 1.92e-03 | 45 | 27 | 2 | IPR002401 | |
| Domain | Cyt_P450_CS | 2.65e-03 | 53 | 27 | 2 | IPR017972 | |
| Domain | CYTOCHROME_P450 | 3.06e-03 | 57 | 27 | 2 | PS00086 | |
| Domain | - | 3.16e-03 | 58 | 27 | 2 | 1.10.630.10 | |
| Domain | p450 | 3.16e-03 | 58 | 27 | 2 | PF00067 | |
| Domain | Cyt_P450 | 3.38e-03 | 60 | 27 | 2 | IPR001128 | |
| Domain | RhoGAP | 3.72e-03 | 63 | 27 | 2 | PF00620 | |
| Domain | RHOGAP | 3.84e-03 | 64 | 27 | 2 | PS50238 | |
| Domain | RhoGAP_dom | 3.84e-03 | 64 | 27 | 2 | IPR000198 | |
| Domain | - | 3.84e-03 | 64 | 27 | 2 | 1.10.555.10 | |
| Domain | Rho_GTPase_activation_prot | 7.14e-03 | 88 | 27 | 2 | IPR008936 | |
| Pubmed | 2.16e-06 | 3 | 30 | 2 | 26520442 | ||
| Pubmed | 5.58e-05 | 13 | 30 | 2 | 34140513 | ||
| Pubmed | Loss of Anks6 leads to YAP deficiency and liver abnormalities. | 1.09e-04 | 18 | 30 | 2 | 32886109 | |
| Pubmed | 1.21e-04 | 298 | 30 | 4 | 30737378 | ||
| Pubmed | Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. | 1.35e-04 | 20 | 30 | 2 | 17251353 | |
| Pubmed | Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic disease. | 1.50e-04 | 21 | 30 | 2 | 27591083 | |
| Pubmed | 2.88e-04 | 29 | 30 | 2 | 27358050 | ||
| Pubmed | 4.52e-04 | 421 | 30 | 4 | 36976175 | ||
| Pubmed | Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. | 6.65e-04 | 44 | 30 | 2 | 12745259 | |
| Pubmed | 6.67e-04 | 467 | 30 | 4 | 30194290 | ||
| Pubmed | Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. | 7.27e-04 | 46 | 30 | 2 | 23555292 | |
| Pubmed | An atlas of combinatorial transcriptional regulation in mouse and man. | 8.51e-04 | 877 | 30 | 5 | 20211142 | |
| Pubmed | LATS1/2 suppress NFκB and aberrant EMT initiation to permit pancreatic progenitor differentiation. | 8.59e-04 | 50 | 30 | 2 | 31323030 | |
| Cytoband | 2p13.3 | 2.56e-04 | 36 | 30 | 2 | 2p13.3 | |
| Cytoband | 11q23.3 | 1.20e-03 | 78 | 30 | 2 | 11q23.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2p13 | 3.80e-03 | 140 | 30 | 2 | chr2p13 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr11q23 | 9.10e-03 | 220 | 30 | 2 | chr11q23 | |
| GeneFamily | PHD finger proteins | 4.39e-03 | 90 | 20 | 2 | 88 | |
| GeneFamily | Pleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing | 2.15e-02 | 206 | 20 | 2 | 682 | |
| ToppCell | Globus_pallidus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Hpcal4_(Substantia_Innominata_(SI))--|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.92e-06 | 43 | 29 | 3 | 05de4f11e7315dce19efed14605d7e1704d61b3a | |
| ToppCell | Globus_pallidus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Hpcal4_(Substantia_Innominata_(SI))-|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.92e-06 | 43 | 29 | 3 | ba1a8fd3119a26b65722898276045bf5ecf59768 | |
| ToppCell | Globus_pallidus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Hpcal4_(Substantia_Innominata_(SI))|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.92e-06 | 43 | 29 | 3 | f1e6e1c386851e773f8aa44f112ebf7fdb887df1 | |
| ToppCell | Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|World / Lineage, Cell type, age group and donor | 6.33e-06 | 187 | 29 | 4 | 81cc8435b2704a9a8287b3f54acaae0f11dd4ac7 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 7.17e-06 | 193 | 29 | 4 | 3866667dd221612589ae50f5c52f73a183a49ce6 | |
| ToppCell | primary_visual_cortex-Neuronal-glutamatergic_neuron-L6b-L6b_Hsd17b2|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.77e-05 | 78 | 29 | 3 | e5dbb0986cbee58fb1e5e464a3b003c4136246e7 | |
| ToppCell | PND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.10e-04 | 144 | 29 | 3 | 46177f0d6117e701bda86a99ac2a1b0e7ed66177 | |
| ToppCell | TCGA-Head_and_Esophagus-Primary_Tumor-Esophageal_Carcinoma-Adenocarcinoma-3|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9 | 1.15e-04 | 146 | 29 | 3 | e55b4acecf4e363b5afa287c747c2e58c4597f3a | |
| ToppCell | TCGA-Head_and_Esophagus-Primary_Tumor-Esophageal_Carcinoma-Adenocarcinoma|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9 | 1.22e-04 | 149 | 29 | 3 | 92a8931a51db619fb5f0638d319c02e7838f6559 | |
| ToppCell | 390C-Myeloid-Macrophage-SPP1+_Macrophage_2|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 1.51e-04 | 160 | 29 | 3 | 8aaf6ac4f33ea291387fdbf9ff1a91d559391774 | |
| ToppCell | Basal_cells-IPF_04|World / lung cells shred on cell class, cell subclass, sample id | 1.59e-04 | 163 | 29 | 3 | 679e25e5548d157d49a73057a3b5617dccda260f | |
| ToppCell | Control-Epithelial_cells-Airway_basal|Control / group, cell type (main and fine annotations) | 1.83e-04 | 171 | 29 | 3 | 3965ced4be6db14265a90673502fceee425837ca | |
| ToppCell | 343B-Myeloid-Macrophage-FABP4+_Macrophage_proliferating_2|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 1.86e-04 | 172 | 29 | 3 | e9b97f37bb1732ad9aa89c5e9b513d14022801ac | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2-Exc_L5-6_FEZF2_ANKRD20A1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.93e-04 | 174 | 29 | 3 | 99eb5e1aee136c7039e23b68a43a0fa3d775859f | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D122|Adult / Lineage, Cell type, age group and donor | 2.00e-04 | 176 | 29 | 3 | 3fee8a367bb9755aca1b7fcc968b08e51b6e9436 | |
| ToppCell | Control-Lymphoid-B|World / Disease state, Lineage and Cell class | 2.17e-04 | 181 | 29 | 3 | 9124f1a610cfc3355ad87921cd3eb5346956475d | |
| ToppCell | TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Adenocarcinoma_Mixed_Subtype|TCGA-Lung / Sample_Type by Project: Shred V9 | 2.17e-04 | 181 | 29 | 3 | c783c2ecca7ab8e07646fa92dc7d436d24939d03 | |
| ToppCell | Control-Epithelial_cells-Airway_club|Control / group, cell type (main and fine annotations) | 2.17e-04 | 181 | 29 | 3 | c755d23dd9aabc717dc73e2b3fa99a1f751e6507 | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.20e-04 | 182 | 29 | 3 | 770ce9f3f4538d0181a0181543841bc964c68274 | |
| ToppCell | TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-7|TCGA-Prostate / Sample_Type by Project: Shred V9 | 2.20e-04 | 182 | 29 | 3 | af16334fec2c757b03c84cf252d00e92fa81e4cd | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.20e-04 | 182 | 29 | 3 | 77ab860e2add49dad0c1ffbfc64278ad499dfbd5 | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial-hepatocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.20e-04 | 182 | 29 | 3 | 4921c7d5687cc79f896b39753bb621d7e3d2972f | |
| ToppCell | Control-Epithelial_cells-Airway_mucous|Control / group, cell type (main and fine annotations) | 2.24e-04 | 183 | 29 | 3 | 15d24a4fb1ffe6cbafbd54fcd7dde9ddcfbe03b2 | |
| ToppCell | Control-Endothelial-Endothelial-Activated_Alv_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.24e-04 | 183 | 29 | 3 | e81c142770f44fd902b0631bc360c5b5339d4c75 | |
| ToppCell | Control-Epithelial_cells-Airway_goblet|Control / group, cell type (main and fine annotations) | 2.27e-04 | 184 | 29 | 3 | d92a71441e4e19f8c301999d8186f8e48e3cd162 | |
| ToppCell | COVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations) | 2.31e-04 | 185 | 29 | 3 | cfe6fd73d817e173fe803bc1683c291d9bcb8608 | |
| ToppCell | Control-Epithelial-Club|World / Disease state, Lineage and Cell class | 2.35e-04 | 186 | 29 | 3 | 9798428691408e17ff2af2fe2d1b345f074d67e4 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.38e-04 | 187 | 29 | 3 | f124d2c699b717b7c02a1a70493f515b83dc2f4c | |
| ToppCell | RA-10._Endothelium_II|World / Chamber and Cluster_Paper | 2.46e-04 | 189 | 29 | 3 | 75c248b9de5e2fb7a0baa8cdbab516e575cc4394 | |
| ToppCell | RA-10._Endothelium_II|RA / Chamber and Cluster_Paper | 2.46e-04 | 189 | 29 | 3 | c81787a8c662db5d7814c583dd64562857629e81 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.46e-04 | 189 | 29 | 3 | e32172ad09e93f6ac6ea2b92145b2b73003f7970 | |
| ToppCell | Control-Endothelial-Endothelial-Alv_Gen_Intermediate|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.46e-04 | 189 | 29 | 3 | 5d7ae1ead7f4fbaeec26f651833c9c2106e1e4d1 | |
| ToppCell | droplet-Fat-BAT+GAT+MAT-30m-Endothelial-endothelial_cell|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.50e-04 | 190 | 29 | 3 | c8370c922e0cf0e0c36e02e1ed2b4053ad6a8073 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Alv_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.50e-04 | 190 | 29 | 3 | 474cbbab8f3b0a6881fa6c92edb78e43999f9ab0 | |
| ToppCell | Adult-Epithelial-club_cell|Adult / Lineage, Cell type, age group and donor | 2.50e-04 | 190 | 29 | 3 | 756bff697d30aec56c0ebfca94295f084a15bf37 | |
| ToppCell | droplet-Fat-BAT+GAT+MAT-30m-Endothelial-nan|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.50e-04 | 190 | 29 | 3 | 5174f91a880f85bb20806023aa68bd4b8ca24ea5 | |
| ToppCell | droplet-Fat-BAT+GAT+MAT-30m-Endothelial|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.50e-04 | 190 | 29 | 3 | 90e494cbfbed33a3a0d29bb7dae83f0c81580bcf | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.54e-04 | 191 | 29 | 3 | 3c464645d0e7e423f791bd63bf5bcf11f6b590d3 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.54e-04 | 191 | 29 | 3 | 1c1d13144259b998d4a0e85142f7afef2ef1e63f | |
| ToppCell | Children_(3_yrs)-Epithelial|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.54e-04 | 191 | 29 | 3 | e432c6e1ae82dddf84314ce73d2b7a991630d905 | |
| ToppCell | Children_(3_yrs)-Epithelial-club_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.54e-04 | 191 | 29 | 3 | 23776c7302cead3881b39127398f3b3e0d27885e | |
| ToppCell | IPF-Epithelial-Club|World / Disease state, Lineage and Cell class | 2.54e-04 | 191 | 29 | 3 | 3c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954 | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.58e-04 | 192 | 29 | 3 | c07d7b40b2aa4eb27ac85801c014a656e2fd01dc | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.58e-04 | 192 | 29 | 3 | 04f5a2e3dd6beff027b89d66eefdd92036e041af | |
| ToppCell | Control-Epithelial-Club|Control / Disease state, Lineage and Cell class | 2.58e-04 | 192 | 29 | 3 | d84ed1ea4a03edaa18c804f75afb03bd7b1f0e16 | |
| ToppCell | RV-10._Endothelium_II|RV / Chamber and Cluster_Paper | 2.62e-04 | 193 | 29 | 3 | 01c2df9206f1527c578e808978e58196c35e72f5 | |
| ToppCell | nucseq|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.62e-04 | 193 | 29 | 3 | 779276e775cb2492e8dd36436295a536084a6415 | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.62e-04 | 193 | 29 | 3 | 02f633b016ab19bfa65bfd0cf32f000549a62148 | |
| ToppCell | RV-10._Endothelium_II|World / Chamber and Cluster_Paper | 2.62e-04 | 193 | 29 | 3 | 2531266bc57339d4e2b22a88817008e32b8c1598 | |
| ToppCell | Epithelial-club_cell|World / Lineage, Cell type, age group and donor | 2.62e-04 | 193 | 29 | 3 | 2bdd09004fa433550958ec42ba4b06271a4aaf7c | |
| ToppCell | Control-Endothelial-Endothelial|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.62e-04 | 193 | 29 | 3 | aff0649c73c634bc6ff0dc7759b4693a9236bf05 | |
| ToppCell | Control-Endothelial|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.62e-04 | 193 | 29 | 3 | c5f9fe03e64c211d4bcd4959e5b32f14841e336a | |
| ToppCell | LPS-antiTNF-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.62e-04 | 193 | 29 | 3 | 5122b1ffba42de190061be34ecdc6176f84e56a3 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.62e-04 | 193 | 29 | 3 | 82e8a4c40299ffcdfd5a0da711bb9de6fb8a2eaa | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.66e-04 | 194 | 29 | 3 | 0b9cd96fa0b616da7cc90e92ff71157e9bba518f | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-Secretory/RAS-RAS|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.66e-04 | 194 | 29 | 3 | a58841b34efe673671a9a059238e044a7254b279 | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.66e-04 | 194 | 29 | 3 | 1d39d968730a7e85b6161c1c8a6bd38afe9bcad7 | |
| ToppCell | LPS-IL1RA-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.66e-04 | 194 | 29 | 3 | 43f92b0533e26633dc94cce554045d641ef8fd76 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-Secretory/RAS|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.66e-04 | 194 | 29 | 3 | 0cd4363627acd419e00d6d32f6dce10430aa6487 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.70e-04 | 195 | 29 | 3 | 6477e6e7be5bd8eb99119a12ae16334ccddecd43 | |
| ToppCell | normal_Lung-Epithelial_cells-Club|normal_Lung / Location, Cell class and cell subclass | 2.70e-04 | 195 | 29 | 3 | b46544ad5af04f4dbc2643637caa3d2d50d922ae | |
| ToppCell | COPD-Multiplet|COPD / Disease state, Lineage and Cell class | 2.74e-04 | 196 | 29 | 3 | 6d02d494196e3f857d53eea46d9419690d43beca | |
| ToppCell | severe_influenza-CD8+_Tem|World / disease group, cell group and cell class (v2) | 2.74e-04 | 196 | 29 | 3 | 40fb254abcab2e65affc5d6037e71893a031d264 | |
| ToppCell | COPD-Multiplet-Multiplet|COPD / Disease state, Lineage and Cell class | 2.74e-04 | 196 | 29 | 3 | af4cdc61830685a888a1209826c23bcf54a43084 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_basal-Basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.78e-04 | 197 | 29 | 3 | 1e915957ea6a4550ecb9d6ee4b232aa5800faf20 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.78e-04 | 197 | 29 | 3 | fdb92985f7df0c280b87d3e43c2394e70786a2c7 | |
| ToppCell | 10x3'2.3-week_17-19-Endothelial-stroma-tip_EC|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.78e-04 | 197 | 29 | 3 | b212ff28ca2d1fea4140f186ab90941bdca21249 | |
| ToppCell | nucseq-Endothelial|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.78e-04 | 197 | 29 | 3 | ebf9be068eaa658493fa7884fd19f34642922acb | |
| ToppCell | Epithelial_cells-Basal_cells|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id | 2.82e-04 | 198 | 29 | 3 | 4235005c49fc2b29ad3a0ee6b608f0109d04f775 | |
| ToppCell | 10x3'2.3-week_17-19-Endothelial-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.82e-04 | 198 | 29 | 3 | 1e83bec16dcd60460422625f89952ff506d6be51 | |
| ToppCell | 10x3'2.3-week_17-19-Endothelial|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.82e-04 | 198 | 29 | 3 | 2630a7a6e56febe5c0b0bde70dd7292fa1650c47 | |
| ToppCell | wk_15-18-Endothelial|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 2.82e-04 | 198 | 29 | 3 | dcf453e22dba90c0ae349fa6c3d4c20758bb95af | |
| ToppCell | NS-critical-d_07-13|critical / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.82e-04 | 198 | 29 | 3 | a6e11c87b31beffb6af190c64b4ef3ee1d9dab8d | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.86e-04 | 199 | 29 | 3 | 8bf8d7cd774479f065bbbbcb5a4bd1aa91aa0d85 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.86e-04 | 199 | 29 | 3 | 0c060ef64341659f4b1247d0264ac12e53a7e12e | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_basal-Suprabasal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.86e-04 | 199 | 29 | 3 | f5c3561744e2a0e7716657cb521acb1d8f054b41 | |
| ToppCell | facs-Trachea-nan-3m-Mesenchymal|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.86e-04 | 199 | 29 | 3 | 67f78c070c56e44fba36542041bf7fa1c291807c | |
| ToppCell | facs-Trachea-nan-3m-Mesenchymal-nan|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.86e-04 | 199 | 29 | 3 | 1ae244b563f85c1ee8d22698f478c842a4d9c7f5 | |
| ToppCell | Bronchial_Biopsy-Epithelial|Bronchial_Biopsy / Tissue, Lineage and Cell class of Lung Cells from 10X | 2.86e-04 | 199 | 29 | 3 | ef5d8917c8d011184830a0b8197afc6266707b37 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Epithelial|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.90e-04 | 200 | 29 | 3 | f386a86b127433cbac306950443355bd723080ff | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Epithelial-Epithelial,_Airway|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.90e-04 | 200 | 29 | 3 | b75154417c215b8853186bff46d624ebd387ac4f | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated|COVID-19_Mild / Disease, condition lineage and cell class | 2.90e-04 | 200 | 29 | 3 | 2281debd86e5d92e8fe0397aec9ef670800f7471 | |
| ToppCell | NS-moderate-d_0-4-Epithelial|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.90e-04 | 200 | 29 | 3 | 64462a18afca3c1a8548a857924b8166058bf958 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.90e-04 | 200 | 29 | 3 | 8827653738a931e4a4545e0c7d75be12bed40740 | |
| ToppCell | Tracheal-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.90e-04 | 200 | 29 | 3 | d3af0a706baf66e3f32e67b17dcfc31e5b32ce0e | |
| ToppCell | 5'-Airway_Nasal|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.90e-04 | 200 | 29 | 3 | f6e967738b4f7b173d6e9977e305f77380dd6c8a | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Epithelial-Epithelial,_Airway-squamous_epithelial_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.90e-04 | 200 | 29 | 3 | 1c02a7f4047d1d2208cc522c6bb4a4989d7845bb | |
| ToppCell | ILEUM-non-inflamed-(7)_CD36+_endothelial_cells|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.90e-04 | 200 | 29 | 3 | 45755a597725015dc3ee36f9166f9e82f6f9c603 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Epithelial-Epithelial,_Airway-squamous_epithelial_cell-Epi-Squamous|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.90e-04 | 200 | 29 | 3 | 03051d2190244208905e1611019d4b8fd200bae0 | |
| ToppCell | 5'-Airway_Nasal-Epithelial|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.90e-04 | 200 | 29 | 3 | 358d71329921451c7f5a56f1db0f9989af2299dc | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Gad2_(generic_SN/VTA_GABAergic_neuron)--|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 4.82e-04 | 50 | 29 | 2 | d902816790b9499793708fca2c7d2fa8025cfd2a | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Gad2_(generic_SN/VTA_GABAergic_neuron)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 4.82e-04 | 50 | 29 | 2 | 318112bc843e6bcb6636fa8bdb05270f5fb4eda2 | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Gad2_(generic_SN/VTA_GABAergic_neuron)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 4.82e-04 | 50 | 29 | 2 | 8903d7bd7c2fd2f4c06af7166ab210871a482b13 | |
| Disease | alkaline phosphatase measurement | 2.36e-06 | 1015 | 27 | 8 | EFO_0004533 | |
| Disease | endometrial endometrioid carcinoma | 4.41e-05 | 11 | 27 | 2 | EFO_1001514 | |
| Disease | Malignant neoplasm of breast | 3.52e-04 | 1074 | 27 | 6 | C0006142 | |
| Disease | bone density | 4.07e-04 | 388 | 27 | 4 | EFO_0003923 | |
| Disease | total blood protein measurement | 7.03e-04 | 449 | 27 | 4 | EFO_0004536 | |
| Disease | peripheral arterial disease, traffic air pollution measurement | 7.29e-04 | 194 | 27 | 3 | EFO_0004265, EFO_0007908 | |
| Disease | serum gamma-glutamyl transferase measurement | 1.29e-03 | 914 | 27 | 5 | EFO_0004532 | |
| Disease | information processing speed, response to cranial radiation therapy | 1.29e-03 | 58 | 27 | 2 | EFO_0004363, EFO_0010950 | |
| Disease | Drugs used in diabetes use measurement | 1.60e-03 | 255 | 27 | 3 | EFO_0009924 | |
| Disease | serum albumin measurement | 1.95e-03 | 592 | 27 | 4 | EFO_0004535 | |
| Disease | response to selective serotonin reuptake inhibitor | 2.56e-03 | 82 | 27 | 2 | EFO_0005658 | |
| Disease | Autism Spectrum Disorders | 2.75e-03 | 85 | 27 | 2 | C1510586 | |
| Disease | cholelithiasis | 2.94e-03 | 88 | 27 | 2 | EFO_0004799 | |
| Disease | HbA1c measurement | 3.13e-03 | 675 | 27 | 4 | EFO_0004541 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| MWALKKPFQPFQRTR | 511 | Q8WUY9 | |
| RQRPGKMTWPNNIVK | 211 | Q9UBL3 | |
| SSMPWNKRQPKLQGK | 431 | Q08J23 | |
| RKPTVKRPTMWNVSN | 376 | Q8N9V6 | |
| RPQSNWKESANKMSP | 1141 | Q9BY89 | |
| SQQWARPRFTQPSKM | 141 | Q8N441 | |
| IQSTNWQTMRFKPPP | 401 | P48506 | |
| DNVNRRSWKSFMPPN | 126 | O94854 | |
| SPRQLFKASNMTQRW | 2201 | P50851 | |
| MKKSQSRPLQWDSTP | 271 | Q86V85 | |
| TVPAIWKQPAKQFMR | 206 | Q96MM6 | |
| MKQTWQSKPRNRPSF | 386 | O43283 | |
| NPMQQKWTKPARAGS | 316 | O14523 | |
| NNPELWKTTRPFFMK | 136 | P11511 | |
| MSVWQQRKSRGKLPP | 21 | P20853 | |
| PMRTFNKWRSGEPNN | 221 | Q9BWP8 | |
| PTKNMSPKEQFWGRQ | 736 | Q92613 | |
| TWRNRKPPERKMSQN | 101 | Q9GZY0 | |
| PTNKKMRRNRFKWGP | 226 | P35680 | |
| SLMRSQSPKAQPQTW | 546 | Q14134 | |
| WRRFPMKKSQNSPLG | 76 | Q96KW2 | |
| ASNDPRNFVPNKMWK | 21 | Q96F05 | |
| SMKRNPNAPVTKAGW | 51 | Q9Y2H5 | |
| LWKTAFSAMTQNPRP | 1951 | O60673 | |
| DWKMQSRKRTQTLPN | 431 | P42331 | |
| VFLANKQWMPPRSNR | 401 | A8MT19 | |
| TDNNNPKRWSKPRKR | 246 | Q63HK5 | |
| LWSQKPVQMARPSAR | 136 | Q71RG6 | |
| FNKRAETQMPWSSPR | 221 | Q8N393 | |
| LMMNFQPPSKAWRAS | 816 | Q6UXY8 | |
| QPPSKAWRASQMMTF | 821 | Q6UXY8 | |
| LFNSVMNPKPSSWRK | 31 | Q9GZV5 |